Skip to main content
Clinical Trials/NCT01150760
NCT01150760CompletedNot Applicable

Comparison of Clinical Outcomes in Bowel Resection Patients Receiving Alvimopan vs. Patients Not Receiving Alvimopan in the Premier Perspective/Care Science Database

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 site in 1 country7,050 target enrollmentStarted: April 2010Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
7,050
Locations
1
Primary Endpoint
Percentage of Patients Who Died

Study Overview

Brief Summary

Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis.

The primary objective of this retrospective observational trial is to assess postoperative morbidity and mortality as reported during the index hospitalization for bowel resection and 15/30-day readmissions of alvimopan vs. non-alvimopan matched patients in the combined Premier/Care Science database(a large medical claims database).

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ≥ 18 years at discharge
  • Medical claim with an ICD-9-CM procedure code for a primary procedure (identified at position 1 or 2 involving large or small segmental bowel resection with primary anastomosis
  • Discharged within the study dates
  • Surgery at a participating Premier/Care Sciences hospital

Exclusion Criteria

  • Had a diverting ostomy without a primary anastomosis during the index hospitalization
  • Had a trauma diagnosis
  • Had bowel resections performed on more than 1 day during index hospitalization (this includes cases where a bowel resection and intestinal anastomosis were performed on different days during the index hospitalization)
  • Had an excluded non-bowel resection surgical code (i.e., code for a major non-BR surgical procedure [eg., nephroureterectomy, total joint replacement] in position 1 or 2

Arms & Interventions

Alvimopan Users

Intervention: Alvimopan (Drug)

Outcomes

Primary Outcomes

Percentage of Patients Who Died

Time Frame: Participants were followed up until their hospital discharge after bowel resection

All-cause

Percentage of Patients With Reported In-hospital Postoperative Gastrointestinal (GI) Morbidity

Time Frame: Participants were followed up until their hospital discharge after bowel resection

GI morbidity will be identified using International Classification of Disease 9th Edition Clinical Modification (ICD-9-CM) diagnosis and procedure codes for paralytic ileus, flatulence, eructation, gas pain, insertion of a nasogastric tube, total parenteral nutrition, peripheral parenteral nutrition, digestive symptom complications, diarrhea following GI surgery, intestinal obstruction, abdominal pain, peritoneal adhesions, unspecified protein-calorie malnutrition, parenteral infusion of concentrated nutritional substances, or enteral infusion of concentrated nutritional substances.

Percentage of Patients With In-hospital Cardiovascular Morbidity

Time Frame: Participants were followed up until their hospital discharge after bowel resection

Cardiovascular morbidity was identified using ICD-9-CM diagnosis and procedure codes for myocardial infarction; other ischemic events; congestive heart failure and shock; arrhythmias; or other cardiovascular events (cardiac complications, peripheral vascular complications).

Percentage of Patients With In-hospital Cerebrovascular Morbidity

Time Frame: Participants were followed up until their hospital discharge after bowel resection

Cerebrovascular morbidity was identified using ICD-9-CM diagnosis and procedure codes for ischemic, thrombotic, embolic or hemorrhagic cerebrovascular accidents; acute but ill-defined cerebrovascular disease; transient cerebral ischemia; syncope; or postoperative cerebrovascular accident.

Percentage of Patients With In-hospital Pulmonary Morbidity

Time Frame: Participants were followed up until their hospital discharge after bowel resection

Pulmonary morbidity was identified using ICD-9-CM diagnosis and procedure codes for pneumonia; infectious pneumonia; respiratory complications, pulmonary collapse; acute respiratory failure or edema; pulmonary congestion and hypostasis; pulmonary/respiratory insufficiency after trauma and/or surgery; dyspnea; or respiratory arrest; transfusion related acute lung injury.

Percentage of Patients With In-hospital Infection Morbidity

Time Frame: Participants were followed up until their hospital discharge after bowel resection

Infection morbidity was identified using ICD-9-CM diagnosis and procedure codes for infection due to central venous catheter; abscess of intestine; peritoneal abscess; sepsis or severe sepsis; infection due to vascular device, implant and graft; urinary tract infection; disruption of internal or external surgical wound; persistent postoperative fistula; or postoperative infection.

Percentage of Patients With In-hospital Thromboembolic Morbidity

Time Frame: Participants were followed up until their hospital discharge after bowel resection

Thromboembolic morbidity was identified using ICD-9-CM diagnosis and procedure codes for pulmonary embolism and infarction; arterial embolism and thrombosis or thrombosis of the lower extremities; vascular disorders of the kidney; acute vascular insufficiency of the intestine; or venous thromboembolism.

Percentage of Patients With In-hospital Other Morbidity

Time Frame: Participants were followed up until their hospital discharge after bowel resection

Other morbidity was identified using ICD-9-CM diagnosis and procedure codes for disruption of wound, decubitus ulcer, or postoperative complications not elsewhere classified.

Percentage of Patients Who Were Readmitted Within 15 Days of Discharge

Time Frame: Within 15 days of discharge from hospitalization for bowel resection

Percentage of Patients Who Were Readmitted Between 16 and 30 Days After Discharge

Time Frame: Between 16-30 days after hospital discharge after bowel resection

Percentage of Patients Who Were Readmitted Within 30 Days of Discharge

Time Frame: Between 0-30 days after hospital discharge after bowel resection

Percentage of Patients Discharged to Various Locations

Time Frame: Hospital discharge after bowel resection

Location of discharge for patients who were admitted to the hospital for their bowel resection from home

Intensive Care Unit Length of Stay

Time Frame: Participants were followed up until their hospital discharge after bowel resection

Secondary Outcomes

  • Postoperative Length of Hospital Stay(Measured from the day after bowel resection to the day of hospital discharge)

Investigators

Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials